Davide Nappi
Overview
Explore the profile of Davide Nappi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
110
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Salmanton-Garcia J, Marchesi F, Navratil M, Piukovics K, Del Principe M, Criscuolo M, et al.
Am J Hematol
. 2024 Dec;
100(3):358-374.
PMID: 39715069
Community-acquired respiratory viral infections (CARV) significantly impact patients with hematological malignancies (HM), leading to high morbidity and mortality. However, large-scale, real-world data on CARV in these patients is limited. This...
2.
Martino E, Derudas D, Rossi E, Terlizzi S, Reddiconto G, Stefanoni P, et al.
Haematologica
. 2024 Nov;
PMID: 39605207
Not available.
3.
Marconi G, Rondoni M, Zannetti B, Zacheo I, Nappi D, Mattei A, et al.
Front Oncol
. 2024 Aug;
14:1400461.
PMID: 39135995
Secondary acute myeloid leukemia (sAML) presents as a complex and multifaceted ensemble of disorders, positioning itself as both a challenge and an intriguing frontier within hematologic oncology. Its origins are...
4.
Martino E, Palmieri S, Galli M, Derudas D, Mina R, Pepa R, et al.
Hematol Oncol
. 2024 May;
42(4):e3290.
PMID: 38818978
The ELOQUENT-3 trial demonstrated the superiority of the combination of elotuzumab, pomalidomide, and dexamethasone (EloPd) in terms of efficacy and safety, compared to Pd in relapsed/refractory multiple myeloma (RRMM), who...
5.
Barila G, Quaglia F, Furlan A, Pescosta N, Bonalumi A, Marcon C, et al.
Ann Hematol
. 2023 Sep;
103(1):125-132.
PMID: 37731147
Treatment of lenalidomide refractory (Len-R) multiple myeloma (MM) patients still represents an unmet clinical need. In the last years, daratumumab-bortezomib-dexamethasone (D-VD) combination was extensively used in this setting, even though...
6.
Gentile M, Vigna E, Palmieri S, Galli M, Derudas D, Mina R, et al.
Haematologica
. 2023 Jul;
109(1):245-255.
PMID: 37439329
In the ELOQUENT-3 trial, the combination of elotuzumab, pomalidomide and dexamethasone (EloPd) proved to have a superior clinical benefit over pomalidomide and dexamethasone with a manageable toxicity profile, leading to...
7.
Canale F, Martino M, Porto G, Verduci C, Console G, Irrera G, et al.
Support Care Cancer
. 2023 May;
31(6):350.
PMID: 37227523
Purpose: CAR-T programs will burden increasingly on healthcare systems, since the implementation of these therapies involves: multidisciplinary team collaboration, post-infusion hospitalization with risk of life-threatening toxicities, frequent in hospital visits...
8.
Nappi D, Tauber M, Sykes D
EJHaem
. 2022 Dec;
3(4):1385-1387.
PMID: 36467823
The TEMPI syndrome is a very rare paraneoplastic syndrome associated with plasma cell dyscrasia and monoclonal gammopathy. First described in 2011, the pathophysiology of TEMPI syndrome is still unknown. Essential...
9.
Martino M, Naso V, Loteta B, Canale F, Pugliese M, Alati C, et al.
Int J Mol Sci
. 2022 Nov;
23(21).
PMID: 36362130
The treatment landscape for hematologic malignancies has changed since the recent approval of highly effective chimeric antigen receptor T-cell therapies (CAR-T). Moreover, more than 600 active trials are currently ongoing....
10.
Cerchione C, Nappi D, Romano A, Martinelli G
Cancers (Basel)
. 2022 Sep;
14(17).
PMID: 36077600
Neutropenia and febrile neutropenia are common and potentially life-threating events associated with chemotherapy treatment in Hodgkin lymphoma (HL). Neutropenia-related infectious events could be an issue both for direct clinical consequences...